MedImmune: Phase III Begins, IMTC Poised as Cancer Key
By Randy Osborne
Friday, May 17, 2013
MedImmune Inc., part of AstraZeneca plc, started the first patient in its Phase III hairy-cell leukemia (HCL) trial with its first-in-class antibody-drug conjugate moxetumomab pasudotox (MP), a CD22 immunotoxin made up of an anti-CD22 antibody fused to a toxin. The molecule binds to CD22, gets internalized and processed, and then releases the toxin payload to blast the tumor.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.